tradingkey.logo

J&J's skin disease drug meets main goal in late-stage study

ReutersMay 9, 2025 12:11 PM

- Johnson & Johnson JNJ.N said on Friday its experimental psoriasis drug met the main goal in a late-stage study on patients 12 years and older.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI